Key points are not available for this paper at this time.
• Immune checkpoint inhibitors show promise in oral cancer treatment. • Pembrolizumab and nivolumab offer new options for OSCC. • Immunotherapy targets immune checkpoints to fight OSCC. • Combining immunotherapy with other treatments enhances efficacy. • Challenges include managing immune-related adverse events in OSCC therapy.
Santosh Patil (Sat,) studied this question.